Between confidentiality and scientific exchange: The place of publication in drug discovery and pharmaceutical research

Science Translational Medicine

Volumn 3, Issue 67, 2011, Pages

  Clozel, Martine ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICINE; CONTINUING EDUCATION; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; EXPERIMENTAL THERAPY; HEALTH EDUCATION; KNOWLEDGE; LIFE EXPECTANCY; NOTE; PATENT; PATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; PROFESSIONAL SECRECY; PUBLICATION; QUALITY OF LIFE; ANIMAL; ARTICLE; CLINICAL TRIAL (TOPIC); CONFIDENTIALITY; ETHICS; HUMAN; METHODOLOGY; PUBLISHING; RESEARCH;

ANIMALS; CLINICAL TRIALS AS TOPIC; CONFIDENTIALITY; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PUBLICATIONS; PUBLISHING; RESEARCH;

EID: 79251481135     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001890     Document Type: Note

References (12)

1. A. S. Kesselheim, Using market-exclusivity incentives to promote pharmaceutical innovation. N. Engl. J. Med. 363, 1855-1862 (2010).
2. K. Strebhardt, A. Ullrich, Paul ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473-480 (2008).
3. C. M. Kalanje, Role of intellectual property in innovation and new product development, www.wipo.int (2005).
4. U.S. Public Law 110-85 (Food and Drug administration Amendments Act of 2007), Title VIII, Section 801.
5. S. McMillan, R. Duska, R. Hamilton, D. Casey, the ethical dilemma of research and development openness versus secrecy. J. Bus. Ethics 65, 279-285 (2006).
6. J. Hunter, S. Stephens, Is open innovation the way forward for big pharma? Nat. Rev. Drug Discov. 9, 87-88 (2010).
7. S. Hopewell, K. Loudon, M. J. Clarke, A. D. Oxman, K. Dickersin, Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst. Rev. (1): MR000006 (2009).
8. A. B. O'Connor, The need for improved access to FDA reviews. J. Am. Med. Assoc. 302, 191-193 (2009).
9. F. Song, S. Parekh, L. Hooper, Y. K. Loke, J. Ryder, A. J. Sutton, C. Hing, C. S. Kwok, C. Pang, I. Harvey, Dissemination and publication of research findings: an updated review of related biases. Health Technol. Assess. 14, iii, ix-xi, 1-193 (2010).
10. R. Shane, Risk evaluation and mitigation strategies: Impact on patients, health care providers, and health systems. Am. J. Health Syst. Pharm. 66 (suppl. 7), S6-S12 (2009).
11. M. D. Lindner, Clinical attrition due to biased preclinical assessments of potential efficacy. Pharmacol. Ther. 115, 148-175 (2007).
12. C. Sudlow, Science, chronic fatigue syndrome, and me. BMJ 340, c1260 (2010).